Exact Sciences is collaborating with the Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients, the company announced recently.

According to a release, the Mayo Clinic will use Exact Sciences’ comprehensive genomic profiling test, OncoExTra, and hereditary cancer test, Riskguard, to help guide therapeutic decisions, advance cancer research and support the development of new diagnostic tests and therapies for cancer treatment.

“This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” Exact Sciences CEO Kevin Conroy said in a statement. “By combining the strength of Exact Sciences’ portfolio of tests with Mayo Clinic’s world-renowned medical and scientific expertise, we’ll help put cancer patients on a path to potentially more effective, targeted therapies and better outcomes.”

Patients will need to consent to have the tests performed and the data shared with Mayo Clinic.